Biogen (BIIB) Exchange Rate Effect (2009 - 2026)
Biogen (BIIB) posted quarterly Exchange Rate Effect of -$18.0 million for Q1 2026, down 152.48% year-over-year from $34.3 million in Q1 2025, and down 820.0% on a QoQ basis from $2.5 million in Q4 2025.
Biogen (BIIB) Exchange Rate Effect (2009 - 2026) Analysis & Trends
Biogen (BIIB) has reported Exchange Rate Effect for 18 consecutive years, with -$18.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Exchange Rate Effect fell 152.48% year-over-year to -$18.0 million; the TTM figure through Mar 2026 stood at $49.6 million (up 581.55% YoY), while the FY2025 annual figure was $101.9 million, up 250.52% from the prior year.
- Exchange Rate Effect came in at -$18.0 million for Q1 2026 at Biogen, down from $2.5 million in the prior quarter.
- The five-year high for Exchange Rate Effect was $68.3 million in Q2 2025, with the low at -$74.4 million in Q4 2024.
- Average Exchange Rate Effect over 5 years is -$258823.5, with a median of -$4.1 million recorded in 2023.
- Across the five-year window, Exchange Rate Effect tumbled 525.0% in 2022 and soared 642.06% in 2025, its largest moves.
- Year by year, Exchange Rate Effect stood at $67.2 million in 2022, then retreated by 28.72% to $47.9 million in 2023, then tumbled by 255.32% to -$74.4 million in 2024, then surged by 103.36% to $2.5 million in 2025, then tumbled by 820.0% to -$18.0 million in 2026.
- According to Business Quant data, Exchange Rate Effect over the past three periods registered -$18.0 million, $2.5 million, and -$3.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FX Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 67.00 Mn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | -25.00 Mn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -12.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -18.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -19.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | -11.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 19.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | -77.00 Mn |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | -18.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.00 Mn |
| Mar 31, 2026 | -18.00 Mn |
| Dec 31, 2025 | 2.50 Mn |
| Dec 31, 2025 | 2.50 Mn |
| Sep 30, 2025 | -3.20 Mn |
| Sep 30, 2025 | -3.20 Mn |
| Jun 30, 2025 | 68.30 Mn |
| Jun 30, 2025 | 68.30 Mn |
| Mar 31, 2025 | 34.30 Mn |
| Mar 31, 2025 | 34.30 Mn |
| Dec 31, 2024 | -74.40 Mn |
| Dec 31, 2024 | -74.40 Mn |
| Sep 30, 2024 | 42.40 Mn |
| Sep 30, 2024 | 42.40 Mn |
| Jun 30, 2024 | -12.60 Mn |
| Jun 30, 2024 | -12.60 Mn |
| Mar 31, 2024 | -23.10 Mn |
| Mar 31, 2024 | -23.10 Mn |
| Dec 31, 2023 | 47.90 Mn |
| Dec 31, 2023 | 47.90 Mn |